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thetical cohort of patients diagnosed with RRMS in the United
States (US). Health states were based on the Kurtzke expanded
disability status scale (EDSS) (higher EDSS scores = increased
disease severity). Relapse and disease progression transition
probabilities for SMA were obtained from natural history
studies. Treatment effects of the immunomodulatory therapies
were estimated by applying a percent reduction to the SMA 
transition probabilities and adjusting for neutralizing antibodies
(NAbs) and treatment discontinuation. Therapy-speciﬁc data
was obtained from clinical trials and long-term follow-up
studies. Transitions among health states occurred in 1-month
cycles for the lifetime of a patient. Costs (2005US$) and out-
comes were discounted at 3% annually. RESULTS: The incre-
mental cost per quality-adjusted life-year (QALY) is $258,465,
$303,008, $395,686, and $310,691 for SCGA, IM-IFNb1-a, 
SC-IFNb1-a and SC-IFNb1-b compared to SMA respectively.
Sensitivity analyses showed results were sensitive to changes in
utilities, disease progression rates, time horizon and
immunomodulatory therapy cost. CONCLUSIONS: Model
results indicated that the immunomodulatory therapies are both
more effective and more costly than SMA in treating RRMS.
Although the reported incremental cost-effectiveness ratios
(ICERs) are well above $50,000/QALY, not all economic evalu-
ations are bounded by this threshold and numerous interventions
with ICERs above this threshold have been deemed valuable by
patients, health care decision-makers and society. This model
suggests that of the immunomodulatory therapies for MS SCGA
is the most cost-effective.
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OBJECTIVES: To estimate the cost-effectiveness of topiramate
(TPM) treatment for migraine prevention versus no preventive
treatment using newly available efﬁcacy and cost data.
METHODS: Model inputs included baseline migraine days per
month (base-case: 7), treatment discontinuation, treatment
response, cost of preventive therapy, cost of acute treatment per
attack (medical and pharmacy services), hours of work lost per
attack, and hourly wage. Model outcomes were expressed
monthly and included the number of migraine days averted, dis-
ability hours, total cost of preventive and acute treatment, and
lost wages. Model inputs were gathered from published litera-
ture, clinical studies of TPM in migraine prevention (double-
blind and open-label extensions), and census data. Unit costs for
resource use were obtained by analyzing actual payments of year
2004 medical claims from a large managed care database.
RESULTS: TPM treatment was associated with a mean reduc-
tion in migraine days of 2.4/month, and 6.5 fewer disability
hours. Acute treatment costs per patient per month (including
pharmacy and medical) were $39 lower ($100 versus $139) and
work loss was $65 lower ($125 versus $190) for TPM preven-
tive arm. The incremental monthly cost per patient of TPM pre-
ventive therapy was $109. Consequently, the total cost in TPM
arm was $5 higher than in no-preventive arm ($109-$39-$65);
incremental total cost per migraine day averted was $2 for TPM
versus no preventive therapy. Results are sensitive to the 
baseline migraine rate: as the rate increases, total cost of 
care decreases, with break-even at 7.4 migraine days/month.
CONCLUSIONS: Economic savings (direct and indirect costs)
associated with lower migraine frequency offset approximately
93% of the cost of preventive therapy, suggesting that TPM is a
cost-effective treatment for migraine prevention.
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OBJECTIVES: A new disease modifying agent for the treatment
of MS, natalizumab (Tysabri), was introduced to the market at
the end of 2004 and withdrawn in early 2005 because of two
cases (one fatal) of progressive multifocal leukoencephalopathy
(PML). In the event that natalizumab is reintroduced to the
market, the present study was conducted to assess the cost-
effectiveness of natalizumab compared to interferon beta-1a
(Avonex) and no treatment. Expected value of perfect informa-
tion (EVPI) and partial EVPI (PEVPI) analyses were conducted
to characterize the existing uncertainty in the model parameters.
METHODS: The main analytical technique used in this study
was incremental cost-effectiveness analysis using a Markov
model. Two-level Monte Carlo simulations were performed to
obtain the EVPI and PEVPI estimates. Health care costs were
derived from the literature. The Disability Status Scale (DSS) was
used as the measure of disability; utility values were assigned to
the 10 DSS disability states based on data from the literature.
Cost valuations were based on the direct health-care costs asso-
ciated with disease relapse and medical care in each disability
state expressed in 2005 US dollars. RESULTS: The Markov
cohort analysis returned the following costs and QALYs: No
Treatment—$175,790 and 30.971 QALYs; interferon beta-1a—
$830,861 and 34.391 QALYs; natalizumab—$1,076,327 and
34.497 QALYs. The incremental cost-effectiveness ratios for
interferon beta-1a and natalizumab compared to no treatment
were: interferon beta-1a—$191,541 per QALY gained; natal-
izumab—$255,399 per QALY gained. CONCLUSIONS: Model
inputs were based on a limited number of available studies and
the results should be interpreted with caution. Nevertheless, the
results of this preliminary analysis suggest that treatment with
interferon beta-1a is somewhat more cost-effective than natal-
izumab. The value of information results indicate that more
information about the transition probabilities and QALY para-
meters are necessary to reduce the uncertainty in the model.
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OBJECTIVES: Payers in Europe and North America have dif-
ferent policies on coverage of multiple sclerosis (MS) disease-
modifying agents (DMAs). With the introduction of Medicare
Part D and in the presence of substantial variation in analytical
methods used to examine cost-effectiveness (CE) of MS DMAs,
an assessment of the models’ features and parameters is neces-
sary to understand and interpret the CE results for clinical prac-
tice and health policy. This study compares the results of CE
models evaluating DMAs (interferon beta-1a, interferon beta-1b,
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and glatiramer acetate) vs. conventional therapy for treatment of
MS. METHODS: Search of electronic databases has identiﬁed 8
models. We evaluated the following sources of uncertainty: 1)
variation in population characteristics (age, gender, country); 2)
sources of data on effectiveness, costs, and health preferences; 3)
modeling assumptions (choice and duration of treatment, long-
term treatment effectiveness, time of treatment initiation and ter-
mination); and 4) model structure (number of health states, study
horizon, and modeling software). RESULTS: Results for inter-
feron beta-1a varied from cost-saving to $2,558,660 (2005 US$)
per quality adjusted of life year (QALY), CE of interferon beta-
1b varied from $10,629/QALY to dominated (more costly and
less effective), and results for glatiramer acetate varied from
$165,201/QALY to dominated. Time horizon and treatment
duration varied from 2 years to lifetime. Studies with longer
treatment duration reported worse (higher) CE. All studies 
used country-speciﬁc cost data and performed some sensitivity
analyses, but only 4 models were evaluated for uncertainty.
CONCLUSIONS: Two out of 8 models found interferons cost-
effective, while glatiramer acetate was not CE based on societal
standards. The differences in models’ results were attributed to
the lack of evidence on long-term treatment effectiveness 
and variation in modeling approaches. Use of DMAs could be
justiﬁed for selected subpopulations, if prices were reduced, 
or if more information on long-term treatment effect becomes
available.
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OBJECTIVE: Migraine is a chronic, episodic condition that
places a tremendous burden on the health care system, employ-
ers, patients and families. This study compared the cost-
effectiveness of treating a migraine with one dose of eletriptan
40mg or sumatriptan 100mg during a 24-hour period.
METHODS: This study used data from a randomized, placebo-
controlled trial to compare the cost-effectiveness of eletriptan 40
mg and sumatriptan 100mg in treating acute migraine. Three
effectiveness measures were compared (sustained headache
response at 1 and 2 hours, and sustained pain-free response at
2 hours) over a 24-hour period in deﬁning treatment success. The
total cost of treating all evaluable patients was deﬁned as the
total cost of the triptans used by patients up to 24 hours after
the ﬁrst dose. The cost per successfully treated patient (CPSTP)
was calculated for each of the three deﬁnitions of treatment
success using the following formula: [CPSTP = Total triptan cost
of treating evaluable patients/ Number of successfully treated
patients] RESULTS: For the 1-hour sustained headache response,
the CPSTP estimates were $103 (95% CI: $89–122) for eletrip-
tan and $149 (95% CI: $126–177) for sumatriptan. For the 2-
hour sustained headache response, the estimates were $48 (95%
CI: $44–53) and $67 (95% CI: $60–76) for eletriptan and suma-
triptan, respectively. For the 2-hour sustained pain-free response,
the estimates were $90 (95% CI: $79–105) for eletriptan and
$151 (95% CI: $127–181), for sumatriptan. The beneﬁt of
eletriptan 40mg over sumatriptan 100mg is clear for all three
measures of success. CONCLUSIONS: The CPSTP, calculated
for each effectiveness measure, was consistently lower for eletrip-
tan 40mg versus sumatriptan 100mg. These results support 
the use of eletriptan 40mg over sumatriptan 100mg in acute
migraine management, and can be used to assist decision makers
in formulary considerations.
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OBJECTIVES: Examine patterns of published economic “value
messages” for anti-epileptic drugs (AEDs). METHODS: Using
literature review best practices, identiﬁed, reviewed, and
abstracted data from comparative economic analyses published
in English and referenced in PubMed or presented at ISPOR. For
each study, documented comparators, “winners” and “losers”,
explanation of economic advantage (if any) study sponsor (if
any), year published, country of interest, and study design.
RESULTS: We identiﬁed 26 studies containing at least one com-
parative economic “value message” for an AED. A total of 57%
(15) were published as manuscripts; 53% (14 of 26) were spon-
sored by a drug manufacturer (4 manuscripts and 10 conference
abstracts); and 38% (10 of 26) were US-oriented. Of the 14
sponsored studies, Ortho-McNeil (topiramate) sponsored 6
(only 1 published; only 1 US-oriented); UCB (levetiracetam) 4;
Novartis (carbamazepine, oxcarbazepine) 3; and GSK (lamot-
rigine) 1. With only one exception (Ortho-McNeil), sponsored
studies generated positive messages for sponsors’ products. The
26 studies generated 39 comparative messages. There was at
least one “winning” message for 11 of the 13 AEDs studied. Top-
iramate was the most frequent “winner” (35% of all messages
expressed economic superiority of topiramate over compara-
tors). Lamotrigine was the most frequent “loser” (45% of all
economic messages). There was at least one message showing
economic superiority over lamotrigine for 7 of the 13 AEDs. For
generically available AEDs, the explanation for cost savings
stemmed from lower drug price, with no evidence of clinical infe-
riority. For levetiracetam, the explanation for cost-effectiveness
stemmed from reduced seizure frequency, a better side effect
proﬁle, and improved adherence. The rationale for topiramate’s
economic advantages was unclear from conference abstracts.
CONCLUSIONS: Several manufacturers of branded AEDs
(Ortho-McNeil, UCB, Novartis) have produced studies describ-
ing their drug’s economic value, while others have done very little
work in this area. Patterns emerge in methods and comparators.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin, a
new add-on antiepileptic, as an adjunct to standard therapy (ST)
in adult patients with refractory partial epilepsy (RPE).
METHODS: We developed a stochastic model to estimate
expected outcomes and costs over one year for a hypothetical
cohort of 1000 RPE patients assumed to receive pregabalin 
(300mg/d, 600mg/d) plus ST or ST alone. Model outcomes
included numbers of days free of seizures (“seizure-free [SF]
days”) and quality-adjusted life-years (QALYs); the latter were
assumed to depend on seizure frequency and side effects. Costs
included those of antiepileptics only. Number of days with
